SGN-40

SGN-40 (also known as denintuzumab mafodotin or SGN-CD40M) is a monoclonal antibody designed for the treatment of cancer. This drug was developed by Seattle Genetics.

Mechanism of Action[edit | edit source]

SGN-40 is a monoclonal antibody that targets the CD40 molecule, which is overexpressed in many types of B-cell malignancies. The antibody is linked to a potent cytotoxic agent, monomethyl auristatin F (MMAF), which is released inside the cancer cell after the antibody binds to the CD40 molecule. This leads to the death of the cancer cell.

Clinical Trials[edit | edit source]

Several clinical trials have been conducted to evaluate the safety and efficacy of SGN-40. These trials have included patients with non-Hodgkin lymphoma, multiple myeloma, and chronic lymphocytic leukemia. The results of these trials have shown that SGN-40 can induce responses in a significant proportion of patients, even those with advanced disease.

Side Effects[edit | edit source]

The most common side effects of SGN-40 include fatigue, nausea, and diarrhea. Less common side effects include neutropenia, anemia, and thrombocytopenia. In some cases, these side effects can be severe and may require dose reductions or discontinuation of treatment.

Future Directions[edit | edit source]

Research is ongoing to further evaluate the potential of SGN-40 in the treatment of B-cell malignancies. This includes studies to determine the optimal dosing schedule and to evaluate the drug in combination with other treatments.

SGN-40 Resources
Need Help Finding a Doctor? Need help finding a doctor or specialist anywhere in the world? Explore our world directory. WikiMD's DocFinder can assist you in locating millions of physicians.	Medical Knowledge Access the latest research - Most recent articles Ongoing trials.